search
Back to results

Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH) (ARAMIS)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Low dose of Micardis®
Medium dose of Micardis®
High dose of Micardis®
Hydrochlorothiazide
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

35 Years - 84 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • At least 35 years, but less than 85 years of age
  • Mean SBP ≥ 150 mm Hg and mean DBP < 90 mm Hg at the randomisation visit (visit 2), according to WHO definitions of ISH (excluding the subgroup of borderline ISH)
  • Hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient (investigator's discretion)
  • Ability to provide written informed consent

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:

    1. are not surgically sterile; and/or
    2. are nursing
    3. are of child-bearing potential and are not practicing acceptable means of birth control or do NOT plan to continue using this method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives
  • Mean systolic blood pressure ≥ 180 mmHg at the randomization Visit 2
  • Known or suspected secondary hypertension
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    1. Serum glutamic pyruvate transaminase (ALT) or serum glutamic oxaloacetic transaminase (AST) > than 2 times the upper limit of normal range
    2. Serum creatinine > or 1.8 mg/dl (or 159 µmol/l)
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney
  • Clinically relevant hypokalemia or hyperkalemia
  • Uncorrected volume or sodium depletion
  • Primary aldosteronism
  • Hereditary fructose intolerance
  • Biliary obstructive disorders
  • Symptomatic congestive heart failure
  • Angina pectoris or previous myocardial infarction
  • Previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft
  • Previous cerebrovascular accident or hypertensive encephalopathy or transient ischemic attack(s)
  • Current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigators decision) by the start of the run-in period. Any pre-treatment with diuretics, ACE inhibitors or angiotensin II receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out
  • Atrial fibrillation (controlled or otherwise) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator
  • Hemodynamically relevant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle
  • Patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history:

    1. Fasting blood glucose less than 200 mg/dl (11.1 mmol/l)
    2. Therapy stabilized for at least one month prior to start of placebo run-period
  • Patients with diabetes mellitus requiring treatment with insulin
  • Patients who have previously experienced symptoms characteristics of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
  • Known drug or alcohol dependency
  • Any investigational therapy within one month of signing the informed consent form and during the trial
  • Known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides
  • Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ)
  • Gout (contraindication for treatment with HCTZ)
  • Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm Type

    Experimental

    Experimental

    Experimental

    Active Comparator

    Placebo Comparator

    Arm Label

    Low dose of Micardis®

    Medium dose of Micardis®

    High dose of Micardis®

    Hydrochlorothiazide

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change from baseline in seated systolic blood pressure at trough (24 hours post-dose)
    Change from baseline in urine albumine excretion rate
    Change from baseline in pulse wave velocity

    Secondary Outcome Measures

    Percentage of patients achieving a target fall in SBP
    Changes in seated diastolic blood pressure (DBP)
    Change from baseline in augmentation index
    Incidence and intensity of adverse events
    Number of patients with relevant changes from baseline in physical examination
    Number of patients with relevant changes in Heart Rate (HR)
    Number of patients with relevant changes in laboratory parameters
    Number of patients with relevant changes in 12-lead electrocardiogram (ECG)

    Full Information

    First Posted
    June 25, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02175355
    Brief Title
    Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
    Acronym
    ARAMIS
    Official Title
    A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    October 1999 (undefined)
    Primary Completion Date
    August 2000 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Primary: To identify doses of Micardis®(telmisartan) which, administered once daily, are more effective than placebo and not inferior to HCTZ in lowering systolic blood pressure (SBP) in patients with isolated systolic hypertension (ISH), and to assess the dose response relationship of the antihypertensive effect of telmisartan over the dose range of 20 to 80 mg. Secondary: Target fall in SBP, change from baseline in seated DBP. Safety and tolerability of Micardis® and HCTZ in patients with ISH as measured by changes in physical examinations, heart rate, laboratory parameters and/or 12-lead ECG, as well as the incidence and severity of adverse events.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    1039 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Low dose of Micardis®
    Arm Type
    Experimental
    Arm Title
    Medium dose of Micardis®
    Arm Type
    Experimental
    Arm Title
    High dose of Micardis®
    Arm Type
    Experimental
    Arm Title
    Hydrochlorothiazide
    Arm Type
    Active Comparator
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Low dose of Micardis®
    Intervention Type
    Drug
    Intervention Name(s)
    Medium dose of Micardis®
    Intervention Type
    Drug
    Intervention Name(s)
    High dose of Micardis®
    Intervention Type
    Drug
    Intervention Name(s)
    Hydrochlorothiazide
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Change from baseline in seated systolic blood pressure at trough (24 hours post-dose)
    Time Frame
    after 6 weeks of treatment
    Title
    Change from baseline in urine albumine excretion rate
    Time Frame
    after 6 weeks of treatment
    Title
    Change from baseline in pulse wave velocity
    Time Frame
    after 6 weeks of treatment
    Secondary Outcome Measure Information:
    Title
    Percentage of patients achieving a target fall in SBP
    Time Frame
    after 6 weeks of treatment
    Title
    Changes in seated diastolic blood pressure (DBP)
    Time Frame
    up to 6 weeks
    Title
    Change from baseline in augmentation index
    Time Frame
    after 6 weeks of treatment
    Title
    Incidence and intensity of adverse events
    Time Frame
    up to 6 weeks
    Title
    Number of patients with relevant changes from baseline in physical examination
    Time Frame
    baseline, week 6
    Title
    Number of patients with relevant changes in Heart Rate (HR)
    Time Frame
    up to 6 weeks
    Title
    Number of patients with relevant changes in laboratory parameters
    Time Frame
    up to 6 weeks
    Title
    Number of patients with relevant changes in 12-lead electrocardiogram (ECG)
    Time Frame
    up to 6 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    35 Years
    Maximum Age & Unit of Time
    84 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: At least 35 years, but less than 85 years of age Mean SBP ≥ 150 mm Hg and mean DBP < 90 mm Hg at the randomisation visit (visit 2), according to WHO definitions of ISH (excluding the subgroup of borderline ISH) Hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient (investigator's discretion) Ability to provide written informed consent Exclusion Criteria: Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who: are not surgically sterile; and/or are nursing are of child-bearing potential and are not practicing acceptable means of birth control or do NOT plan to continue using this method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives Mean systolic blood pressure ≥ 180 mmHg at the randomization Visit 2 Known or suspected secondary hypertension Hepatic and/or renal dysfunction as defined by the following laboratory parameters: Serum glutamic pyruvate transaminase (ALT) or serum glutamic oxaloacetic transaminase (AST) > than 2 times the upper limit of normal range Serum creatinine > or 1.8 mg/dl (or 159 µmol/l) Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney Clinically relevant hypokalemia or hyperkalemia Uncorrected volume or sodium depletion Primary aldosteronism Hereditary fructose intolerance Biliary obstructive disorders Symptomatic congestive heart failure Angina pectoris or previous myocardial infarction Previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft Previous cerebrovascular accident or hypertensive encephalopathy or transient ischemic attack(s) Current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigators decision) by the start of the run-in period. Any pre-treatment with diuretics, ACE inhibitors or angiotensin II receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out Atrial fibrillation (controlled or otherwise) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator Hemodynamically relevant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle Patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history: Fasting blood glucose less than 200 mg/dl (11.1 mmol/l) Therapy stabilized for at least one month prior to start of placebo run-period Patients with diabetes mellitus requiring treatment with insulin Patients who have previously experienced symptoms characteristics of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists Known drug or alcohol dependency Any investigational therapy within one month of signing the informed consent form and during the trial Known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ) Gout (contraindication for treatment with HCTZ) Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.254_U01-1348.pdf
    Description
    Related Info

    Learn more about this trial

    Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

    We'll reach out to this number within 24 hrs